The most common adverse events of grade 3 or worse were anaemia ( 11 [ 8 % ] of 132 patients in the gefitinib group and five [ 4 % ] of 132 patients in the placebo group ) and neutropenia ( nine [ 7 % ] and seven [ 5 % ] ) .